Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
"It's very hard for her to go out to a lot of places in public right now because her lungs are so compromised. The medicine ...
IFLScience on MSN1d
Inhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical TrialsA new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
GlobalData on MSN1d
Boehringer and partners commence gene therapy trial for cystic fibrosisBoehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...
The genetic disorder cystic fibrosis is unique because it can cause both breathing and digestive problems. Some 40,000 people in the U.S. currently have it, "though this is likely an ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback